淋巴细胞CD28通路活化后Th1／Th2细胞因子mRNA表达及CsA的 …

采用ＲＴ－ＰＣＲ方法，观察ＣＤ２８通路活化后淋巴细胞Ｔｈ１／Ｔｈ２细胞因子ｍＲＮＡ表达水平及ＣｓＡ的抑制作用。取正常人外周血淋巴细胞，培养过程中分别给予抗ＣＤ３ｍＡｂ单独刺激或抗ＣＤ３ｍＡｂ＋抗ＣＤ２８ｍＡｂ共同刺激。提取细胞总ＲＮＡ并逆转录成ｃＤＮＡ，对Ｔｈ１细胞因子基因ｍＲＮＡ转录增加，且对ＣｓＡ的抑制作用产生抵抗；而对Ｔｈ２细胞因子则不产生明显影响。研究表明：ＣＤ２８共刺激信号主要增强淋巴细     

抗CD3与抗CD28单克隆抗体共刺激对淋巴细胞免疫活化基因mRNA表达的影响

目的　观察ＣＤ２８ 共刺激信号对淋巴细胞免疫活化基因表达的影响及环孢素Ａ（ＣｓＡ）对它们的抑制作用。方法　分离健康人外周血单个核细胞, 分别给予抗ＣＤ３ 单克隆抗体（ 抗ＣＤ３ｍＡｂ） 单刺激或抗ＣＤ３ ｍＡｂ＋ 抗ＣＤ２８ 单克隆抗体（抗ＣＤ２８ ｍＡｂ）共刺激培养; 加或不加入ＣｓＡ。于培养后６ ｈ 和２４ ｈ 收集细胞。以逆转录聚合酶链反应（ＲＴＰＣＲ） 检测βＡｃｔｉｎ、ＣＤ４０Ｌ、ｂｃｌｘＬ、ＴＧＦβ１ 、Ｆａｓ、ＦａｓＬ、穿孔素和颗粒酶ＢｍＲＮＡ 表达水平。结果　ＣＤ２８ 共刺激信号能显著增强免疫活化基因ｍＲＮＡ 的表达;ＣｓＡ 对ＦａｓＬ和颗粒酶Ｂ的ｍ ＲＮＡ表达能产生抑制, 而对共刺激后其余免疫活化基因的表达无明显抑制。结论　ＣＤ２８ 共刺激信号通过提高多种Ｔ 淋巴细胞相关的免疫活化基因的表达水平, 而使免疫反应的活化、增殖和效应过程均得到增强;ＣｓＡ 对这一过程并非完全无效, 仍可能具有调节作用。     

淋巴细胞CD28通路活化后Th1/Th2细胞因子mRNA表达及CsA的抑制作用

采用ＲＴＰＣＲ方法，观察ＣＤ２８通路活化后淋巴细胞Ｔｈ１／Ｔｈ２细胞因子ｍＲＮＡ表达水平及ＣｓＡ的抑制作用。取正常人外周血淋巴细胞，培养过程中分别给予抗ＣＤ３ｍＡｂ单独刺激或抗ＣＤ３ｍＡｂ＋抗ＣＤ２８ｍＡｂ共同刺激。提取细胞总ＲＮＡ并逆转录成ｃＤＮＡ，对Ｔｈ１细胞因子（ＩＦＮγ、ＩＬ２）和Ｔｈ２细胞因子（ＩＬ４、ＩＬ１０）ｃＤＮＡ进行扩增。结果显示：共刺激信号可使Ｔｈ１细胞因子基因ｍＲＮＡ转录增加，且对ＣｓＡ的抑制作用产生抵抗；而对Ｔｈ２细胞因子则不产生明显影响。研究表明：ＣＤ２８共刺激信号主要增强淋巴细胞Ｔｈ１细胞因子基因ｍＲＮＡ表达，并可能参与其分化调节；这一活化通路不被ＣｓＡ阻断。     

抗CD3与抗CD28单克隆抗体共刺激对淋巴细胞免疫活化基因m …

目的 观察ＣＤ２８共刺激信号对淋巴细胞免疫活化基因表达的影响及环孢素Ａ（ＣｓＡ）对它们的抑制作用。方法 分离健康人外周血单个核细胞,分别给予抗ＣＤ３单克隆抗体（抗ＣＤ３ｍＡｂ）单刺激或抗ＣＤ３ｍＡｂ＋抗ＣＤＷ２８单克隆抗体（抗ＣＤ２８ｍＡｂ）共刺激培养;加或不加入ＣｓＡ。于培养后６ｈ和２４ｈ收集细胞。以逆转录聚合酶链反应（ＲＴ－ＰＣＲ）检测β－Ａｃｔｉｎ、ＣＤ４０Ｌ、ｂｃｌ－ｘＬ、ＴＧＦ－β１、Ｆ     

CsA、MPA和RPM对CD_(28)通路共刺激后淋巴细IL-4 mRNA表达的影响

目的　观察环孢素Ａ（ＣｓＡ） 、霉酚酸（ ＭＰＡ） 和雷帕霉素（ＲＰＭ） 对ＣＤ２８ 通路共刺激后淋巴细胞ＩＬ４ ｍ ＲＮＡ 表达的影响。　方法　以ＰＣＲ 扩增方法获得ＩＬ４ 特异的ｃＤＮＡ 片段,并将其克隆至ＰＧＥＭ３Ｚ 载体中。以此作为探针对ＲＴＰＣＲ 产物进行杂交定量,比较三种免疫抑制剂对ＣＤ２８通路共刺激后淋巴细胞ＩＬ４ ｍ ＲＮＡ 表达的影响。　结果　以抗ＣＤ３ ｍ Ａｂ ＋ 抗ＣＤ２８ ｍ Ａｂ 共刺激后,发现淋巴细胞稳定地表达ＩＬ４ ｍ ＲＮＡ;ＣｓＡ 和ＭＰＡ 未能抑制淋巴细胞ＩＬ４ ｍ ＲＮＡ 的表达,而ＲＰＭ则能产生显著抑制。　结论　ＲＰＭ 能抑制ＣＤ２８ 通路共刺激后ＩＬ４ ｍ ＲＮＡ 的表达,而ＣｓＡ 和ＭＰＡ对这一过程无抑制作用。     

CsA,MPA和RPM对CD28通路共刺激后淋巴细胞IL—4mRNA表达？…

目的 观察环孢素Ａ（ＣｓＡ）霉酚酸（ＭＰＡ）和雷帕霉素（ＲＰＭ）对ＣＤ２８通路共刺激后淋巴细胞ＩＬ－４ｍＲＮＡ表达的影响。方法 以ＰＣＲ扩增方法获得了ＩＬ－４特异的ｃＤＮＡ片段，并将其克隆至ＰＧＥＭ－３Ｚ载体中，以此作为探针对ＲＴ－ＰＣＲ产物进行杂交定量，比较三种免疫抑制剂对ＣＤ２８通路共刺激后淋巴细胞ＩＬ－４ｍＲＮＡ表达的影响。结果 以抗ＣＤ３ｍＡｂ＋抗ＣＤ２８ｍＡｂ共刺激后，发现淋巴细胞稳定地     

CTLA－4Ig的免疫抑制作用

ＣＴＬＡ－４Ｉｇ是一种通过基因重组产生的可溶性嵌合蛋白，和ＡＰＣｓ表面Ｂ７分子有高度亲合力．Ｂ７和Ｔ细胞表面的ＣＤ２８／ＣＴＬＡ－４结合能产生共刺激信号，使Ｔ细胞充分活化，从而产生对移植物的排斥反应，ＣＴＬＡ－４Ｉｇ能与ＣＤ２８竞争性地结合３７分子，阻断共刺激信号的发生，产生免疫抑制作用。ＣＴＬＡ－４Ｉｇ与目前常用免疫抑制剂的作用机理不同，有可能诱导供者抗原特异性免疫耐受。本文综述ＣＴＬＡ－４Ｉｇ的作用机理及其在移植免疫研究中的应用。     

CTLA—4Ig的免疫抑制作用

ＣＴＬＡ－４Ｉｇ是一种通过基因重组产生的可溶性嵌合蛋白，和ＡＰｓ表面的Ｂ７分子有高度亲合力，Ｂ７和Ｔ细胞表面的ＣＤ２８／ＣＴＬＡ－４结合能产生共刺激信号，使Ｔ细胞充分活化，从而产生对移植物的排斥反应，ＣＴＬＡ－４Ｉｇ能与ＣＤ２８性地结合Ｂ７分子，阻断共刺激信号的发生，产生免疫抑制作用，ＣＴＬＡ－４Ｉｇ与目前常用免疫抑制剂的作用机理不同，有可能诱导供者抗原特异性免疫耐受。本文综述ＣＴＬＡ－４Ｉｇ的任     

肝癌特异性细胞毒 T 淋巴细胞的实验及临床研究

诱导肿瘤特异性细胞毒性Ｔ细胞（ＴＳ－ＣＴＬｓ），观察其体外、体内的抗肿瘤作用及其特异性；评价其抗肝癌术后复发的临床应用价值。方法：用细胞因子体外短期刺激方法提高肝癌细胞的免疫原性，再与肿瘤浸润Ｔ细胞共同培养，辅以ＣＤ２８单抗共刺激，诱导ＴＳ－ＣＴＬｓ，检测其体内外抗肝癌作用及其效应机制；大量扩增后回输患者，观察其免疫学指标的变化并随访其术后复发情况。结果：体外研究表明，肝癌细胞经ＩＦＮ－γ、ＴＮＦ－α诱导后ＭＨＣＩ类分子，ＩＣＡＭ－１及Ｂ７分子的表达增高，用此细胞辅以ＣＤ２８单抗刺激诱导产生的ＴＳ－ＣＴＬｓ体现了高度的对自体肝癌的杀伤活性及特异性，其杀伤活性由ＴＣＲ－ＣＤ３复合物、ＣＤ８、ＬＦＡ－１、ＩＣＡＭ－１及ＭＨＣＩ类分子所介导。体内研究的结果表明，ＴＳ－ＣＴＬｓ对ＳＣＩＤ小鼠人肝癌模型具有显著的抑瘤作用。１２例初步临床应用的结果表明，ＴＳ－ＣＴＬ对于提高机体的Ｔ细胞免疫功能，对于预防肝癌术后复发均具有良好作用，值得进一步深入研究和应用。结论：ＴＳ－ＣＴＬｓ作为一种新的肿瘤特异性免疫治疗方法可望进一步提高肝癌和其它实体肿瘤的外科综合治疗水平。     

针对T细胞活化共刺激通路的抗移植排斥研究进展

１概述 Ｔ细胞在移植排斥反应中起着核心作用。Ｔ细胞活化、产生细胞因子及克隆增殖的过程需要两种信号参与：信号１由Ｔ细胞受体（ＴＣＲ）与抗原递呈细胞（ＡＰＣ）表面的ＭＨＣ－抗原复合物相互作用时产生,具有抗原特异性;信号２即共刺激信号,由可溶性共刺激分子或ＡＰＣ表面的分子配体提供,若缺乏共刺激信号,Ｔ细胞将进入免疫无应答状态。因此,信号１决定了免疫反应的特异性,信号２则决定了免疫反应的程度和转归。自９０年代初较系统地提出上述Ｔ细胞活化双信号模式后,该领域的研究日益受到重视。Ｔ细胞表面ＣＤ２８分子与ＡＰ…     

The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.

The effect of the CD28 activation pathway on the immunosuppressive action of CsA was assessed. Human peripheral blood lymphocytes were stimulated with anti-CD3, bryostatin (Bryo) a novel activator of protein kinase C (PKC) and anti-CD28 singly or in combination, to which graded doses of CsA were added to determine relative sensitivity. Proliferation, IL-2 production, and IL-2 receptor expression were assessed and the IC50 determined. Lymphocytes stimulated with Bryo exhibited a marginal proliferative response but expressed the IL-2 receptor despite the presence of CsA. Addition of anti-CD3 or anti-CD28 to Bryo-stimulated lymphocytes promoted a vigorous proliferative response. CsA effectively inhibited the proliferative response and IL-2 production induced with anti-CD3 and Bryo but did not inhibit the response of cells stimulated with anti-CD28 and Bryo. However, II-2 receptor expression in both sets of cultures were comparable due to the induction of IL-2 receptor by Bryo and was not inhibited by CsA. Costimulation of lymphocytes with anti-CD3 plus anti-CD28 resulted in a 2-3-fold enhancement of proliferation compared with lymphocytes stimulated with anti-CD3 alone. Addition of CsA to lymphocytes stimulated with anti-CD3 resulted in the dose-dependent suppression of the proliferative response and IL-2 production (IC50 = 10-25 nM) but less so for IL-2 receptor expression (IC50 = 100-150 nM). In comparison, the proliferative response and IL-2 production elicited by anti-CD3 + anti-CD28 was more resistant to the effects of CsA (IC50 = 100-200 nM). However, IL-2 receptor expression exhibited comparable sensitivity to CsA (IC50 = 100-200 nM) in the presence of anti-CD28. Combination drug:drug studies revealed that CsA and the protein kinase C inhibitor H-7 were additive for both anti-CD3 and anti-CD3 plus anti-CD28 response. On the other hand, the cGMP-dependent protein kinase inhibitor H-8 was synergistic with CsA in inhibiting the response of lymphocytes to anti-CD3 plus anti-CD28 but only additive for responses to anti-CD3. Taken together, these data suggest that CsA inhibits T cell activation at two distinct levels, leading to inhibition of IL-2 production and inhibition of IL-2 receptor expression. Activation of the CD28 pathway partially overcomes the inhibitory activity of CsA on IL-2 production and may be mediated by indirect activation of a cGMP-dependent protein kinase.(ABSTRACT TRUNCATED AT 400 WORDS)     

Activation-Induced Expression of Cell Surface CD28 on Mouse T Lymphocytes is Inhibited by Cyclosporine A

T-cell activation requires both T-cell receptor signaling and a costimulatory signal provided by CD28 which enhances and prolongs interleukin-2 (IL-2) production. To determine the effect of cyclosporine A (CsA) on constitutive and activation-induced CD28 expression, mouse T cells were exposed to CsA (0.1 microM) in the absence or presence of anti-CD3 monoclonal antibody (mAb). CD28 expression was then determined by flow cytometry. CsA treatment prevented activation-induced CD28 expression but did not affect constitutive CD28 expression. Inhibition of inducible CD28 expression by CsA was not rapidly reversible, requiring 48h of restimulation in the absence of CsA for CD28 expression to return to control levels. T cells activated in the presence of combined anti-IL-2 and anti-CD25 mAb (both 10 microg/mL) also exhibited reduced CD28 expression, suggesting that activation-induced CD28 expression is, at least in part, an IL-2-dependent process. However, the inhibitory effect of CsA on activation-induced CD28 expression was maintained in the presence of exogenous IL-2 (250 U/mL). We conclude that CsA, by inhibiting activation-induced expression of costimulatory CD28 molecules by T lymphocytes, may interfere with the ability of CD28 to provide an optimal costimulatory signal for sustained IL-2 production following T-cell activation.     

Evidence that genistein, a protein-tyrosine kinase inhibitor, inhibits CD28 monoclonal-antibody-stimulated human T cell proliferation.

In the present investigation, we compared the immunosuppressive effects of genistein and CsA on anti-CD28 stimulated human T cell proliferation, IL-2 production, and IL-2R expression. Genistein, an isoflavanoid compound, is a specific protein tyrosine kinase inhibitor and inhibited the PMA plus anti-CD28 stimulated T cell proliferation. In contrast, proliferation of T cells stimulated with PMA plus anti-CD28 is resistant to the inhibitory effects of CsA. Similar results were obtained with IL-2 synthesis and IL-2R expression. PHA plus anti-CD28 or PMA plus anti-CD28-induced IL-2 synthesis was inhibited by genistein, and CsA, though it inhibited the PHA plus PMA-stimulated IL-2 synthesis, failed to have any effect on PMA plus anti-CD28-induced IL-2 synthesis. Genistein at the concentration that inhibited T cell proliferation and IL-2 synthesis also showed significant inhibitory effects on PMA plus anti-CD28 stimulated IL-2R expression while CsA had no effect on IL-2R from these cultures. Our data suggest that genistein is a powerful immunosuppressive agent, with no toxic effects on T cells, and has the potential for use in the prophylaxis and treatment of allograft rejection. Since genistein blocks the CsA-resistant pathway of T cell proliferation, the combined usage of these two agents may provide better immunosuppressive effect and a lesser degree of CsA-induced nephrotoxicity.     

The effects of immunosuppressants on FAS-mediated activation-induced cell death in human T lymphocytes

The effects of cyclosporin A (CsA) and methylprednisolone (MP) on Fas-mediated activation-induced cell death (FMAICD) of T lymphocytes were examined. T lymphocytes were activated with the immobilized anti-CD 3 and CD 28 monoclonal antibodies (MoAbs) (activation phase) and incubated further with the agonistic MoAb against Fas (death phase). Cell proliferation and DNA fragmentation were measured by XTT and diphenylamine assay. CsA in the activation phase inhibited DNA fragmentation mediated by anti-Fas MoAb but not MP. The combination of CsA and MP at the lower concentrations had little effect on FMAICD, although they had similar degrees of suppression on T lymphocyte proliferation as the maximum obtained by CsA or MP alone. In the death phase, MP induced apoptosis without 7C11 and CsA had no effects. These results indicate that the combination of CsA and MP at low concentrations could maintain FMAICD with the suppression on T lymphocyte proliferation.     

西罗莫司和环孢素A对Th17细胞和调节性T淋巴细胞分化影响的比较

目的 比较西罗莫司(SRL)和环孢素A(CsA)对体外诱导CD4+T淋巴细胞向Th17和调节性T淋巴细胞分化的影响.方法 使用抗CD3和抗CD28单克隆抗体(简称抗CD3单抗和抗CD28单抗)刺激CD4+T淋巴细胞,并在培养体系中分别加入转化生长因子β(TGF-β);TGF-β+白细胞介素6(IL-6);TGF-β+IL-6+SRL;TGF-β+IL-6+CsA.72 h后用流式细胞术检测细胞内Foxp3和IL-17的表达水平,观察CD4+T淋巴细胞的分化情况及SRL和CsA对CD4+T淋巴细胞体外分化的影响.结果 在经抗CD3单抗和抗CD28单抗刺激后,TGF-β可诱导Foxp3+细胞(调节性T淋巴细胞,Treg)的增殖与分化,而TGF-β+ID6可诱导Th17细胞的增殖与分化.在培养体系中加人SRL和CsA,均可使Th17细胞的增殖与分化减少;SRL可促进Treg的增殖与分化,而CsA抑制Treg的增殖与分化.结论 SRL可以促进CD4+T淋巴细胞向Treg增殖与分化,而抑制Th17细胞的增殖与分化;CsA既抑制Treg的增殖与分化,又抑制Th17细胞的增殖与分化.     

T CELLS ACTIVATED IN VITRO AS IMMUNOTHERAPY FOR RENAL CELL CARCINOMA: CHARACTERIZATION OF 2 EFFECTOR T-CELL POPULATIONS

PURPOSE: Effector T cell populations generated using 2 methods of in vitro activation are currently being tested in separate clinical trials as immunotherapy for patients with advanced cancer, including renal cell carcinoma. To determine the most appropriate method of activation for cancer immunotherapy in vitro antitumor activity of the 2 effector T-cell populations were compared. METHODS AND METHODS: The effector T-cell populations were generated concurrently by activation of peripheral blood mononuclear cells from patients with advanced renal cell carcinoma or other cancer using soluble anti-CD3 monoclonal antibody (3T cells) or anti-CD3 and anti-CD28 monoclonal antibodies immobilized on beads (3/28T cells). After 14-day culture the phenotype and functional activity of the cells were tested. RESULTS: Fold expansion of CD4(+) cells for 3T cultures was lower than for 3/28T cultures but expansion of CD8(+) cells was similar for both cultures. Expression of CD69 was higher on 3T cells. 3T and 3/28T cells exhibited similar ability to kill various human tumor cell lines. Although both effector T-cell populations produced Th1-type cytokines upon re-stimulation, 3T cells secreted a higher level of interferon-gamma and tumor necrosis factor-alpha compared with 3/28T cells. Intracellular cytokine analysis demonstrated that the percent of cells producing interferon-gamma was higher in CD4(+), CD8(+), CD25(+), CD69(+) and CD45RO(+) 3T cells compared with 3/28T cells. CONCLUSIONS: These data suggest that 3T cells may have increased efficacy as immunotherapy for patients with cancer due to higher levels of tumoricidal cytokine production than 3/28T cells.     

Increased protein synthesis after T cell activation in presence of cyclosporin A

BACKGROUND: The immunosuppressive drug, cyclosporin A (CsA), blocks immune responses by inhibiting the calcineurin-dependent dephosphorylation of the nuclear factor of activated T cells (NFAT). We have previously reported that T cells activated in presence of CsA exhibit particular properties. In our study, we have tested the hypothesis that T cells activated in presence of CsA display a differential pattern of gene expression. METHODS: T lymphocytes were activated in vitro by Concanavalin A with or without CsA. The cells were: (1) pulsed with 35S-methionine to label the newly synthesized proteins that in turn were revealed by 2D-gel electrophoresis; (2) analyzed by flow cytometry for activation markers expression; and (3) examined by gel electrophoresis for early tyrosine phosphorylation events. RESULTS: The proteomic patterns of T lymphocytes activated by Concanavalin A, with or without CsA, were compared. In keeping with the well-known effect of the immunosuppressor, many polypeptides were not found in its presence. Remarkably, several newly synthesized polypeptides were detected only when activation was carried out in presence of CsA. In addition, immunologically relevant proteins, such as CD44 and CD69, escape CsA-inhibitory action. Furthermore, CsA did not modify the early protein tyrosine phosphorylation events resulting from T cell triggering. CONCLUSIONS: The present data show that the effect of CsA on protein synthesis is more complex than anticipated. Signaling provided by T cell activation and the blockade of the calcineurin-dependent pathway by CsA results in an altered program of gene expression.     

Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade

AIMS: Belatacept is a new recombinant molecule (CTLA4-Ig) that interferes with the second activation signal of T lymphocytes. CTLA4-Ig induced T cell allograft tolerance in rodents but not in primates. We examined the changes in peripheral lymphocyte subsets, including regulatory T cells, in renal transplant patients treated with Belatacept. METHODS: A cross-sectional immunological study was carried out 6 months after transplantation in 28 patients enrolled in the Belatacept phase II study. Eighteen patients received Belatacept, mycophenolate mofetil and steroids (Belatacept group), while the control group of 10 patients received cyclosporine, mycophenolate mofetil and steroids (CsA group). Lymphocyte subsets were examined by flow cytometry. Foxp3 mRNA expression was measured by quantitative PCR. RESULTS: The number of T lymphocytes and the percentage of CD3+ T cells were similar in both groups. However, the percentage of CD3+ CD4+ T cells was lower in the Belatacept group than in the control CsA group (B=42.5%+/-13.7 vs CsA=52.9%+/-9, p<0.005), and the percentage of CD3+ CD8+ cells was higher in the Belatacept group than in the control (B=32.9%+/-6.7 vs CsA=19.5%+/-8.2, p<0.0002). The percentage of CD19+ cells was similar in both groups. Among CD56+cells, only the percentage of CD16+ cells was significantly higher in the Belatacept group than in the control (B=82%+/-12 vs CsA=59.7%+/-25, p=0.01). Among CD4 and CD8 T cells the percentage of activated lymphocytes expressing CTLA4, HLA-DR or CD40L was similar in both groups. The percentage of CD4+CD25+ T cells was higher in the CsA group. The percentage of regulatory CD4+CD25+ cells with bright CD25 staining was similar in both groups (B=3.6+/-2.3% vs CsA=4.7+/-1.9%, ns) as was the expression of FoxP3. CONCLUSION: Our results indicated that Belatacept did not induce regulatory T cell expansion in vivo. We suggest that Belatacept treatment should be maintained after transplantation to allow graft acceptance.     

小鼠补体调节蛋白对CD4+T淋巴细胞的调控作用及其机制

目的 研究小鼠补体调节蛋白Crry对CD4+T淋巴细胞的调控作用及诱导同种移植免疫低反应性的机制.方法 分离C57BL/6小鼠脾淋巴细胞,用免疫磁珠法分选出CD4+T淋巴细胞后,将CD4+T淋巴细胞分为A、B、C、D、E和F组,分别用抗小鼠CD3、CD28、Crry、CD3/CD28、CD3/Crry和CD3/CD28/Crry抗体共刺激通路与CD4+T淋巴细胞进行反应,采用噻唑蓝(MTT)法检测各组CD4+T淋巴细胞的增殖情况,并采用酶联免疫吸附试验检测CD4+T淋巴细胞培养上清中白细胞介素2(IL-2)、γ干扰素(γ-IFN)、IL-4和IL-10的水平;另外,以BALB/c小鼠和C57BL/6小鼠的脾细胞分别作为刺激细胞和反应细胞,建立同种混合淋巴细胞反应(MLR)体系并加入抗小鼠Crry抗体,通过岍法观察Crry对MLR的影响.结果 D、E、F组的CD4+T淋巴细胞均出现明显增殖,增殖活性显著高于A、B、C组(P<0.05),其中F组显著高于D组和E组(P<0.05),D组和E组间增殖活性的差异无统计学意义.D组CD4+T淋巴细胞经抗CD3/CD28抗体共刺激后,培养上清中γ-IFN和IL-2的水平显著升高,与A、B、C和E组比较,差异均有统计学意义(P<0.05),但与F组的差异无统计学意义;E组CD4+T淋巴细胞经抗CD3/Crry抗体共刺激后,IL-4的水平显著升高,与A、B、C、D组比较,差异均有统计学意义(P<0.05),但显著低于F组(P<0.05);各组间IL-10水平的差异无统计学意义.Crry可以明显抑制MLR中的细胞增殖(P<0.05).结论 补体调节蛋白Crry能刺激CD4+T淋巴细胞的增殖,并使其IL-4的表达升高及抑制IL-2和γ-IFN的表达,从而诱导同种移植免疫低反应性.